Table 2.
Susceptibility testing and PK/PD parameters of levofloxacin against 245 clinical isolates from community-acquired pneumonia
| Bacteria (No. of strains) | MIC90 | 500 mg | 750 mg | ||
|---|---|---|---|---|---|
| (μg/mL) | fCmax/MIC90 | fAUC24 h/MIC90 | fCmax/MIC90 | fAUC24 h/MIC90 | |
| Streptococcus pneumoniae (45) | 1 | 5·3 | 26·8 | 9·3 | 65·9 |
| Haemophilus influenzae (51) | 0·5 | 10·6 | 53·6 | 18·6 | 131·7 |
| Klebsiella pneumoniae (108) | 0·5 | 10·6 | 53·6 | 18·6 | 131·7 |
| Methicillin-susceptible Staphylococcus aureus (36) | 0·25 | 21·3 | 107·2 | 37·2 | 263·5 |
| Methicillin-resistant Staphylococcus aureus (5) | 32 | 0·2 | 0·8 | 0·3 | 2·06 |
The f means the unbound fraction of levofloxacin, the value of which was 0·7. The Cmax and AUC0–24 were the non-compartmental paramters following last dose of levofloxacin in the multiple PK study.